France : PharmaMar lance une étude clinique pivot de phase III ATLANTIS portant sur le PM1183 en association avec la doxorubicine chez des patients atteints de cancer pulmonaire à petites cellules
Italia : PharmaMar avvia uno studio pivotale ATLANTIS di Fase III, per la somministrazione di PM1183 in combinazione con doxorubicina a pazienti affetti da carcinoma polmonare a piccole cellule
MADRID, August 2, 2016 /PRNewswire/ --
PharmaMar (MSE:PHM) today announced the start of a pivotal Phase III ATLANTIS study evaluating efficacy and safety of PM1183 (lurbinectedin) in combination with doxorubicin versus topotecan or the combination VCR (cyclophosphamide, adriamicine (doxorubicin) and vincristine) in patients with small cell lung cancer (SCLC) after the failure of one prior platinum-containing line.
Topotecan is the only drug approved both in USA and Europe for this indication.
...